Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcome of

COVID-19 : A Systematic Review and Meta-analysis Aref A. Bin Abdulhak¹, MD, MSc, Tarek Kashour² ,MD, Anas Noman³, MD, Haytham Tlayjeh⁴,MD, Ala Mohsen⁵ ,MD, Mouaz H. Al-Mallah⁶,MD,MSc, Imad M. Tleyjeh^{7,8,9,10},MD, MSc

- 1. Swedish Heart and Vascular Institute, Swedish Medical Center, 550 17th Ave Suite 680, Seattle, WA 98122, USA
- 2. King Fahad Cardiac Center, College of Medicine, Department of cardiac sciences, King Saud University, Riyadh, Saudi Arabia
- 3. Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA
- 4. Department of Intensive Care, King Abdulaziz Medical City, King Saud bin Abdulaziz for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- 5. Louisiana State University Health Science Center, New Orleans, LA 70112, USA
- 6. Houston Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA
- 7. Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
- 8. Department of Epidemiology, Mayo Clinic, Rochester, MN, USA
- Department of Medicine, Infectious Diseases Section, King Fahad Medical City, PO Box 59046, Riyadh 11525, Saudi Arabia.
- 10. College of Medicine, Al Faisal University, Riyadh, Saudi Arabia

Word counts: 2636

Corresponding author:

Imad M. Tleyjeh, MD, MSc, FACP, FIDSA

Professor of Medicine and Epidemiology

Section of Infectious Diseases, King Fahd Medical City

PO Box 59046, Riyadh 11525, Saudi Arabia

Phone: 00966112889999

Email: itlaygeh@gmail.com

Abstract:

Importance:

There is conflicting evidence about the role of angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in the pathogenesis and outcome of patients infected with acute severe respiratory syndrome coronavirus 2 (SARS-CoV-2) and growing public concerns about their use during this pandemic.

Objective:

We sought to systematically review the literature and perform a meta-analysis about prior use of ACEI/ARBs and outcome of COVID-19 patients.

Data source:

We searched multiple data sources including PubMed , ClinicalTrial.org , and medrxiv.org from November 2019 through May 3, 2020.

Study selection

Any study that reported on the role of ACEIs / ARBs and outcome of COIVD-19 is eligible. Two authors independently reviewed eligible studies and extracted data into a prespecified data collection form.

Data synthesis:

An inverse variance meta-analytic approach was used to pool adjusted odds ratios using a random effect model meta-analysis. I 2 test was used to assess in between studies heterogeneity. The Newcastle–Ottawa quality assessment scale was used to assess the quality of included studies.

Main outcome and Measures:

The association between the prior use of ACEIs / ARBs and the mortality among SARS-CoV-2 infected patients was assessed using pooled OR and 95% confidence interval. For studies that

did not report adjusted effect estimates for mortality, we used their adjusted effect estimate of critical outcome to estimate another pooled OR for critical or fatal outcome and its 95% confidence interval.

Results:

Nine studies were included in this systematic review. The studies included a total of 58,615 patients infected with SARS-CoV-2. Prior use of ACEIs and/or ARBs was associated with a significant reduction of inpatient mortality among SARS-CoV-2 infected patients, with a pooled adjusted OR from 4 studies of 0.33, 95% CI [0.22, 0.49] with no between studies heterogeneity (I2=0%) and with a significant reduction of critical or fatal outcome, with a pooled adjusted OR from 5 studies of 0.32, 95% CI [0.22, 0.46] (I2 =32%).

Conclusion:

Our meta-analysis suggests that use of ACEIs/ARBs is associated with a decreased risk of death or critical outcome among SARS-CoV-2 infected patients. This finding is limited by the observational nature of the included studies. However, it provides a reassurance to the public not to stop prescribed ACEIs/ARBs due to fear of severe COVID-19. It also calls upon investigators and ethics committees to reconsider the ongoing randomized trials of discontinuation of these drugs.

Introduction:

The Coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in December 2019 in Wuhan China and since then spread to the rest of the world. By May 02, 2020, the disease has been reported in 215 countries with over 3 million confirmed cases and over 230,000 deaths¹.

Several studies have demonstrated that subjects with underlying cardiovascular diseases (CVDs) represent a significant proportion of patients with symptomatic COVID-19 disease and were among the highest risk individuals for severe disease and worse prognosis with 5-10 fold increase in mortality²⁻⁵. Additionally, several studies revealed that COVID-19 disease is associated with a number of cardiovascular complications including, heart failure, cardiac arrhythmias, pericarditis, myocarditis and vasculitis and Up to 28% of COVID-19 patients experience elevated troponin levels ⁶⁻¹³.

The newly emerged SARS-CoV- is a betacoronavirus, which is related to the SARS-CoV virus that caused SARS outbreak in 2003 with 80% genomic homology¹⁴. A few studies established that SARS-CoV-2 invades human cells through binding of its spike S-protein to angiotensin converting enzyme 2 (ACE2) with the help of the host TMPRESS2 membrane serine protease that primes the virus Spike (S) protein facilitating its cell entry¹⁵⁻¹⁷. The 3D structure of SARS-CoV-2 binding site indicate that it has improved binding stability and it is estimated that its binding affinity to ACE2 is 10-15 times higher than that of SARS-CoV¹⁸⁻¹⁹.

Angiotensin converting enzyme 2 (ACE2) is a type-I transmembarne glycoprotein that is expressed mainly in the testis, intestine, adipose tissue, cardiovascular system and the lung. It catalyzes the conversion of angiotensin-II to angiotensin (1-7) peptide, which has several cardiovascular protective functions such as vasodilatation, anti-proliferative, anti-fibrotic and anti-inflammatory effects ²⁰. ACE2 also exists as a soluble form and serum levels of ACE2 were found to be elevated in patients with hypertension and heart failure²¹⁻²². Moreover, ACE2 has immune modulating effects as shown in several animal models of acute lung injury including SARS model. Furthermore, in a phase-II human trial, recombinant ACE2 infusion significantly reduced angiotensin-II and IL-6 levels in patients with acute respiratory distress syndrome (ARDS), and observed that non-survivors had higher angiotensin-II in comparison to survivors²⁴. Interestingly, serum angiotensin-II was reported to be significantly increased in patients with COVID-19 disease and correlated positively with lung injury and viral titers²⁵. Another confounding issue is the fact that several animal studies illustrated that ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) upregulate ACE2 expression, which raises concerns that these agents, which are widely used to treat hypertension and other cardiovascular conditions may increase susceptibility to SARS-CoV-2 infection²⁶⁻²⁸. These observations led to the speculation that the patients using ACEIs or ARBs might be more susceptible to SARS-CoV-2 infection and severe COVID-19 disease²⁹. This created a major controversy within the scientific community because of the lack of supporting human data; and hence prompted several scientific societies to issue statements regarding the use of ACEIs and ARBs in patients with COVID-19 disease warning against discontinuation of such medications in the absence of supporting convincing evidence.

Moreover, at least 5 randomized trials in multiple countries plans to enroll COVID-19 patients on prior ACEI/ARBs to investigate whether stopping these drugs would affect COVID-19 outcome.

Therefore, herein we aimed to systematically review the exiting literature and perform a metaanalysis of the available studies examining the role of ACEIs/ARBs in the outcome of COVID-19.

Methods:

A comprehensive systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)³⁰ and Meta-Analysis of Observational Studies in Epidemiology guidelines for reporting systematic review and metaanalysis of observational studies guidelines³¹.

Study selection:

Any study that reported the association between the prior use of angiotensin converting enzyme inhibitor and or angiotensin receptor blocker and the outcomes of infected patients with COVID-19 is eligible. Two authors independently (AB and IT) examined eligible studies.

Search Strategy

Medline was searched from November 2019 through May 3, 2020, without language restriction for eligible studies. Pubmed search keys included (" coronavirus " OR "covid-19" OR "SARS" AND " Angiotensin" OR "Angiotensins"). ClinicalTrial.org and medrxiv.org were also searched using similar PubMed search terms.

Data collection and quality assessment

A data collection form was filled by the two authors independently (AB and AM) and reviewed by the senior author (IT). The form contains information about study's population, study's characteristics, exposure to ACE and or ARB, and outcomes including death and severity of infection with COVID-19.

The eligible studies were assessed according to the Newcastle–Ottawa quality assessment scale (NOS)³². NOS scale rates observational studies based on 3 parameters: selection, comparability between the exposed and unexposed groups, and exposure/outcome assessment. It assigns a maximum of 4 stars for selection, 2 stars for comparability, and 3 stars for exposure/outcome assessment.

Studies with less than 5 stars were considered low quality, 5–7 stars moderate quality, and more than 7 stars high quality. Two reviewers (AN and HT) assessed the quality of the included studies.

Analytical method

An inversed variance meta-analytic approach was used to pool study's adjusted odds (OR) ratio or hazards ratio (HR) with its 95% confidence interval (CI) into a random effects model metaanalysis. The two outcomes that were considered for this analysis were death as the primary outcome of this meta-analysis and when adjusted mortality estimates were not reported, we used critical illness as a surrogate of a combined (critical/fatal) outcome resulting from the infection with SARS-CoV-2. We used adjusted ORs or HRs from propensity score matching whenever available or multivariate analysis to pool the overall effect estimate. We collected data for ACEI and ARB effect estimates separately whenever reported in individual studies. We only included adjusted effect estimates because of the observational design of all included studies.

Heterogeneity among the included studies was assessed using χ^2 and $|^2$ tests. The $|^2$ statistic describes the proportion of variation in treatment estimate that is not related to sampling error³³. A value of zero indicates no heterogeneity, 25%–49% low, 50%–74% moderate, and 75% a high degree of heterogeneity. No formal assessment of publication bias was performed because of the low number of studies as per Cochrane guidelines.

Two-sided P value of < 0.05 was considered statistically significant for all included analyses. The statistical software Review Manager, version 5.3.5 (The Nordic Cochrane Center, The Cochrane Collaboration, 2018, Copenhagen, Denmark) was used for all analyses.

Results:

Search strategy and general characteristics of included studies:

Figure 1 showed the result of our search strategy. A total of 9 studies³⁴⁻⁴² (8 cohort studies and one population-based case control study) met our eligibility criteria. Table 1 shows the general characteristics of included studies. There were four studies from China, one study from the USA, one from United Kingdom, one from Italy, and one study was an international collaboration. A population of 58,615 patients with COVID-19 were included in this systematic review and meta-analysis. Seven out of 9 included studies reported data on our outcome of interest (mortality) but only 4^{34,35,37,41} of them reported adjusted OR. Only one³⁶ paper reported adjusted OR for severity of the illness (for ARBs use only) but did not report on the mortality; thus, it was included in the combined critical/fatal outcome. Therefore, the outcome of interest (combined critical / fatal outcome) included only 5 studies. Four out of 9 studies reported data separately on ACE and ARB. Table 2 summarizes the analytic approach and result of quality

assessment of the included studies. There were only few reported data to perform a separate analysis involving ARBs only.

All studies included in the 2 analyses were of moderate quality but one study³⁴ scored high as adjudicated by NOS scale as shown in Table 2.

Meta-analysis:

Prior use of ACEIs and/or ARBs was associated with a significant reduction of inpatient mortality among SARS-CoV-2 infected patients, with a pooled adjusted OR from 4 studies of 0.33, 95% CI [0.22, 0.49] with no between studies heterogeneity ($|^2=0\%$) and with a significant reduction of critical or fatal outcome, with a pooled adjusted OR from 5 studies of 0.32, 95% CI [0.22, 0.46] ($|^2=32\%$).

Discussion

Findings from our systematic review and meta-analysis suggest that prior ACEIs or ARBs use may be associated with a lower risk of fatal or critical outcome in hospitalized patients with COVID-19 infection.

Although the exact mechanism(s) behind the observed association remains unknown, it could be attributed to several factors including cardioprotective effects of ACEIs and ARBs or their direct effect on lung inflammation, viral replication, cytokine production and/or their effects on the interaction of the virus with the renin-angiotensin-aldosterone system.

Cardiovascular complications are common in patients with pneumonia in general and in COVID-19 patients⁴³. A recent systematic review and meta-analysis of 39 observational studies between 1984 to 2019, involving 92,188 patients, reported cardiac complications in 13.9% (95% confidence interval (CI) 9.6–18.9), acute coronary syndromes in 4.5% (95% CI 2.9–6.5), heart failure in 9.2% (95% CI 6.7–12.2), arrhythmias in 7.2% (95% CI 5.6–9.0) and stroke in 0.71% (95% CI 0.1–3.9) of pooled inpatients data⁴⁴.

Moreover, cardiovascular disease risk factors are common in patients admitted with COVID-19 and this could potentially explain the observed beneficial association between prior use of ACEIs/ARBS and outcomes. In a recent meta-analysis of 7 studies including 1576 COVID-19 patients, the most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0–27.2%) and diabetes (9.7%, 95% CI: 7.2–12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8–13.8%) and respiratory system disease (1.5%, 95% CI: 0.9–2.1%)⁴⁵.

Our findings are concordant with previous studies of ACEIs and ARBs in community acquired pneumonia in general. In a previous systematic review and meta-analysis investigators reported that, compared with control treatments, both ACEIs (seven studies: odds ratio 0.73, 0.58 to 0.92; |²=51%) and ARBs (one randomized controlled trial: 0.63, 0.40 to 1.00) were associated with a decrease in the pneumonia related mortality⁴⁶.

In another single center cohort of patients hospitalized with acute respiratory illness who tested positive for respiratory viruses by PCR, and developed concomitant pneumonia, the continued use of ACEI was associated with a decreased risk of mortality or intubation. Furthermore, those who were on ACEI prior to admission and subsequently discontinued the medication had a higher mortality than those not on an ACEI prior to admission. The authors speculated that the ACEI were discontinued in patients with shock or acute kidney injury, thus representing more severe viral pneumonia than those in whom it was continued throughout their hospital stay⁴⁷.

In another large propensity matched cohort of around 23000 patients aged \geq 65 years hospitalized with pneumonia from the Department of Veterans Affairs, prior ACEI use (OR, 0.88; 95% CI, .80–.97) and inpatient ACEI use (OR, 0.58; 95% CI, .48–.69) was associated with decreased mortality. Prior ARB use (OR, 0.73; 95% CI, .58–.92) and inpatient ARB use (OR, 0.47; 95% CI, .30–.72) was also associated with decreased mortality⁴⁸.

Mechanistically, numerous studies investigated the role of RAAS in the pathogenesis of acute lung injury in different animal models. Indeed, several of them reported increased ACE activity and elevated angiotensin-II levels in acute lung injury induced by sepsis, lipopolysaccharide, acute pancreatitis and ventilator induced injury. In addition, these studies demonstrated that treatment with either ACEIs or ARBs ameliorated acute lung injury in these models ^{49-52.} ACEIs and ARBs seem to exert their protective effect through modulation of inflammatory and immune responses. They led to reduction in inflammatory cytokines, TNF-alpha, IL-1beta and IL-6⁴⁹, inhibition of dendritic cell maturation and Th1 and Th17 cell polarization responses⁵⁰,

and suppression of Rho/ROCK pathway⁵¹. These inflammatory and immune modulating effects of ACEIs and ARBs may have clinical relevance in the context of COVID-19 disease. In a recent study, Meng et al compared hypertensive patients on ACEIs/ARBs with those on other medications and found that patients on ACEIs/ARBs had higher CD3+ and CD+ T cells and a trend of lower IL-6. They also observed that although there was no difference in the viral load between the two groups on admission, patients on ACEIs/ARBs had lower peak viral load⁵³.

The other axis of the RAAS is comprised of ACE2 with its main effect is to counterbalances the deleterious effects of angiotensin-II that is produced by ACE. ACE2 promotes the conversion of angiotensin-I to angiotensin-(1-9) peptide and angiotensin-II to angiotensin-(1-7) peptide, which interacts with the Mas receptor and counteracts the effects of angiotensin-II²⁰. Interestingly, angiotensin-II can reduce cell surface expression of ACE2 through enhanced cleavage of ACE2 by TNF-alpha converting enzyme (TACE/ADAM-17), establishing a feedback mechanism where by angiotensin-II promotes the loss of its negative regulator ⁵⁴. The interaction of angiotensin-II and ACE2 in the context of viral induced acute lung injury have been also well established in the mouse model of SARS where it has been shown that SARS-CoV infection or injection of SARS-CoV Spike protein reduced expression of ACE2 and that treatment with recombinant ACE2 or blocking angiotensin-renin pathway protect mice from lung injury⁵⁵. Similar protective effect by recombinant ACE2 were observed against lethal infection with avian influenza A H5N1 virus⁵⁶. Several other studies in animal models of acute respiratory distress syndrome (ARDS) demonstrated that treatment with recombinant ACE2 or angiotensin-(1-7) peptide attenuate lung injury and improve oxygenation ⁵⁷⁻⁵⁹. Relevant to these animal observations, Reddy et al⁶⁰ reported recently in a pilot study of patients with ARDS that plasma angiotensin-(1-7)/ angiotensin-(1-10) ratio and angiotensin-(1-9)/ angiotensin-(1-10) ratio correlated with survival indicating that ARDS survivors had higher ACE2 activity implying possible protective role of ACE2/angiotensin-(1-7) axis in ARDS. Human experience with recombinant ACE2 therapy in ARDS is very limited ²⁴. However, ongoing clinical trials with recombinant ACE2 in COVID-19 disease will shed light on the utility of such therapy in acute lung injury in humans.

Our inferences from this meta-analysis are, however, weakened by limitations inherent to the meta-analysis and the individual studies. Given the observational design of included studies and retrospective data collection, the possibility that the observed association between ACEI/ARB use and COVID -19 outcome was affected by bias or confounding should be considered. For example, comorbidities and severity of illness are known confounders that are associated with ACEI/ARB intake and mortality and the healthy user effect could theoretically explain a potential role for ACEI/ARB in infection outcome. However, the opposite could also be the case where the sicker patients have more exposure to ACEI/ARB because patients with hypertension and cardiovascular risk factors have higher mortality from COVID. Moreover, the combined effect estimate from the studies that used regression models to adjust for possible confounders including age, comorbidities, and severity of illness—although the models were not uniform—supports our conclusions. As with any observational study, residual confounding cannot be fully excluded.

Given our findings, it becomes ethically concerning to continue to enroll patients in the ongoing randomized trials that are testing the hypothesis that stopping/replacing chronic treatment with ACEI or ARB improves outcomes in symptomatic SARS-CoV2-infected patients. We are aware of at least 5 trials listed on clinicaltrias.gov. (Table 3).

Although our study suggests that there may be an association between prior ACEIs/ARBs intake and outcome of COVID-19 patients, it remains unknown whether de novo initiation of ACEIs/ARBs as an adjunctive therapy for COVID-19 will prove beneficial (Supplement table 1).

Conclusions:

Our meta-analysis suggests that prior use of ACEIs/ARBs is associated with a decreased risk of death or critical outcome among SARS-CoV-2 infected patients. This finding is limited by the observational nature of the included studies. However, it provides a reassurance to the public not to stop prescribed ACEIs/ARBs due to fear of severe COVID-19. It also calls upon investigators and ethics committees to reconsider the ongoing randomized trials of discontinuation of these drugs. Moreover, our findings may help encourage patients'

11

enrollment in the ongoing clinical trials evaluating the therapeutic role of de novo initiation of ACEIs/ARBs in SARS-CoV-2 infection.

Figure legends:

Figure 1: Flow diagram of included studies

Figure 2: Random effect model meta-analysis of the adjusted effect estimates of the association between ACEIs/ARBs user and death from COVID-19

Figure 3: Random effect model meta-analysis of the adjusted effect estimates of the association between ACEIs/ARBs user and critical or fatal outcome from COVID-19

References:

- Coronavirus. World Health Organization [Internet]. Who.int. 2020. Available from: <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019</u>. Accessed May 03, 2020.
- Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available from: <u>https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf</u>. Accessed May 03, 2020.
- 3) Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. [epub ahead of print].
- 4) Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020. [epub ahead of print].
- 5) Bonow RO, Fonarow GC, O'Gara PT and Yancy CW. Association of Coronavirus Disease2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol. 2020 Mar 27, doi: 10.1001/jamacardio.2020.1105
- 6) Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
- 7) Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63(3):364-374.
- 8) Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. [epub ahead of print].
- 9) Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020. [epub ahead of print].
- 10) Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020. [epub ahead of print].
- 11) Lippi G, Lavie CJ and Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020Mar 10. Doi: 10.1016/j.pcad.2020.03.001

- 12) Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B and Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25. Doi:10.1001/jamacardio.2020.0950
- 13) Chapman AR, Bularga A and Mills NL. High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19. Circ. 2020 Apr 6. Doi: 10.1161/CIRCULATIONAHA.120.047008.
- 14) Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I and Research T. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.
- 15) Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C and Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Mar 4. Doi: 10.1016/j.cell.2020.02.052.
- 16) Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H and Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-4.
- 17) Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 2020; 5 (4) 565-569.
- 18) Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L and Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 Mar 30. Doi: 10.1038/s41586-020-2180-5.
- 19) Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A and Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020 Mar 30. Doi: 10.1038/s41586-020-2179-y.
- 20) Patel VB, Zhong JC, Grant MB, Oudit GY. Role of ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ. Res. 2016;118 8)1313-1126.

- 21) Uri K, Fagyas M, Manyine Siket I, Kertesz A, Csanadi Z, Sandorfi G, Clemens M, Fedor R, Papp Z, Edes I, Toth A and Lizanecz E. New perspectives in the renin-angiotensin aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS One. 2014;9:e87845.
- 22) Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L, Sandholm N, Thomas MC, Groop PH and FinnDiane Study G. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertension. 2012;30:375-83.
- 23) Kuba K, Imai Y, Rao S, Gao H, Guo F, Huan Y, Yang P, Zhang Y, Deng W et al. A crucial role of angiotensin-converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005;11:875-879.
- 24) Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M et al. A pilot clinical trial of recombinant human angiotensin converting enzyme 2 in acute respiratory distress syndrome. Crit. Care. 2017;21:234.
- 25) Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C at al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral load and lung injury. Sci China Life Sci. 2020;63:364-374.
- 26) Ferrario CM, Challagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin converting enzyme 2. Circulation. 2005;111:2605-2620.
- 27) Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J, Hofffman A, Abassi Z. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin converting enzyme isoforms in rat with experimental heart failure. Am J Physiol Heart Circ Physiol. 2002;289:H1351-H1358.
- 28) Ishiyama Y, Gallagher PE, Avenil DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970-976.

- 29) Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin– Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760
- 30) Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.
- 31) Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
- 32) Wells G SB, O'Connell D, Peterson J, Welch V, Losos M, tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Published 2018. Accessed March 28, 2018.
- 33) Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. *BMJ*. 2003;327(7414):557-560.
- 34) Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circ Res.* 2020.
- 35) Bean D, Kraljevic Z, Searle T, et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-COVID-19 infection in a multi-sile UK acute Hospital Trust.
- medRxiv 2020.04.07.20056788; doi: https//doi.org/10.1101/2020.04.07.20056788
 36) Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv 2020.03.20.20039586; doi: https//doi.org/10.1101/2020.03.20.20039586.
- 37) Yang G, Tan Z, Lou Z et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-Patients With Hypertension. . medRxiv preprint doi: https://doi.org/10.1101/2020.03.31.20038935

- 38)Zeng Z, Sha T, Zhang Y et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20054825
- 39) Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. *N Engl J Med.* 2020.
- 40) Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. *N Engl J Med.* 2020.
- 41) Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *N Engl J Med.* 2020.
- 42)Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020.
- 43) Long B , Brady W, Koyfman A, et al., Cardiovascular complications in COVID-19, American Journal of Emergency Med- icine, https://doi.org/10.1016/j.ajem.2020.04.048
- 44) Tralhão, A.; Póvoa, P. Cardiovascular Events after Community-Acquired Pneumonia: A Global Perspective with Systematic Review and Meta-Analysis of Observational Studies. J. Clin. Med. 2020, 9, 414.
- 45) Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis.* 2020;94:91-95.
- 46) Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. *BMJ.* 2012;345:e4260.
- 47) Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. *Proc (Bayl Univ Med Cent).* 2018;31(4):419-423.
- 48) Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. *Clin Infect Dis.* 2012;55(11):1466-1473.

- 49) Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, Qi J, Xiao Z. Losartan prevents sepsisinduced acute lung injury and decreases activation of nuclear factor KappaB and mitogent activated protein kinases. Shock. 2009;31(5):500-6.
- 50) Liu J, Zhang PS, Yu Q, Liu L, Yang Y, Guo FM, Qiu HB. Losartan inhibits conventional dendritic cell maturation and Th1 and Th17 polarization responses: Novel mechanisms of preventive effects on lipopolysaccharide-induced acute lung injury. Int. J. Mol. Med. 2012;29(2):269-76.
- 51) Yu QH, Guo JF, Chen Y, Guo XR, Du YQ, Li ZS. Captopril pretreatment protects the lungs against severe acute pancreatitis induced lung injury via inhibiting angiotensin II production and suppression of Rho/ROCK pathway. Kohsiung J. Med. Sci. 2016;32(9):439-45.
- 52) Yao S, Feng D, Wu Q, Li K, Wang L. Losartan attenuates ventilator-induced lung injury. J Surg. Res. 2008;145(1):25-35.
- 53) Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg. Microbes Infect. 2020;9(1):757-760. doi: 10.1080/22221751.2020.1746200.
- 54) Patel VB, Clarke N, Wang Z, Fan D, Paraiuli N, Basu R, Putko B, Kassiri Z, Oudit GY. Angiotensin II induced proteolytic cleavage of myocardial ACE2 mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J. Mol. Cell Cardiol. 2014;167:166-76. doi: 10.1016/j.yjmcc.2013.11.017.
- 55) Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury. Exp. Physiol. 2008;93(5):543-8. doi:10.1113/expphysiol.2007.040048.
- 56) Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, Ju X, Liang Z, Liu Q, Zhao Y, Guo F, Bai T, Han Z, Zhu J, Zhou H, Huang F, Li C, Lu H, Li N, Li D, Jin N, Penninger JM, Jiang C. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat. Commun. 2014;5:3594. doi: 10.1038/ncomms4594.
- 57) Rey-Parra GJ, Vadivel A, Coltan L, Hall A, Eaton F, Schuster M, Loibner H, Penninger JM, Kassiri Z, Oudit GY, Thébaud B. Angiotensin converting enzyme 2 abrogates

bleomycin-induced lung injury. J. Mol. Med. 2012;90(6):637-47. doi: 10.1007/s00109-012-0859-2.

- 58) Zambelli V, Bellani G, Borsa R, Pozzi F, Grassi A, Scanziani M, Castiglioni V, Masson S, Decio A, Laffey JG, Latini R, Pesenti A. Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome. Intensive Care Med. Exp. 2015;3(1):44. doi: 10.1186/s40635-015-0044-3.
- 59) Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, Ju X, Liang Z, Liu Q, Zhao Y, Guo F, Bai T, Han Z, Zhu J, Zhou H, Huang F, Li C, Lu H, Li N, Li D, Jin N, Penninger JM, Jiang C. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat. Commun. 2014;5:3594. doi: 10.1038/ncomms4594.
- 60) Reddy R, Asante I, Liu S, Parikh P, Liebler J, Borok Z, Rodgers K, Baydur A, Louie SG. Circulating angiotensin peptides levels in acute respiratory distress syndrome correlate with clinical outcomes: A pilot study. PLoS One. 2019;14(3):e e0213096. doi: 10.1371/journal.pone.0213096. eCollection 2019.

STUDY/PUBLICATION YEAR	COUNTRY	PUBLICATION STATUS	STUDY TYPE	AGE	MALES (%)	ACEIS / ARBS (N)	NON- ACEIS/ARBS (N)	MORTALITY OR (95% CI)	SEVERE DISEASE OR (95% CI
LI ET AL 2020	China	Published	Retrospective cohort study	66 years (median)	46.3	115	247	0.76 [0.44, 1.33]	1.055 (0.71,1.55)
BEAN ET AL 2020	UK	Preprint	Retrospe <i>c</i> tive cohort study	62.95 years (mean)	51.7	48	1577	0.29(0.10-0.75)	NR
ZHANG ET AL 2020	China	Published	Retrospective cohort study	64 years (median)	54	174	348	0.37 [0.15, 0.89]	0.65 (0.41, 1.04)
LIU ET AL 2020	China	Preprint	Retrospective cohort study	65.2 years (mean)	55	3	56	NR	ARBs: 0.25 (0.064, 0.976)
MANCIA ET AL 2020	Italy	Published	Population based case control study	68 years (mean)	63.3	1502	5,910	NR	1.56 [1.31, 1.87]
MEHRA ET AL 2020	International	Published	Retrospective cohort study	52 years (mean)	62	1326	7584	0.33 (0.20-0.54)	0.33 [0.20, 0.54]
REYNOLDS ET AL 2020	USA	Published	Retrospective cohort study	64 years (median)	50.8	954	3412	NR	ACEI: 0.84 [0.65, 1.09]
YANG ET AL 2020	China	Preprint	Retrospective cohort study	65 years (median)	49	43	83	0.32 [0.07, 1.51]	0.82 (0.407,1.6795)
ZENG ET AL 2020	China	Preprint	Retrospective cohort study	64 years (mean)	43	28	47	0.67 (0.12, 3.69)	1.67 (0.71 ,3.94)


Table 1: General characteristics of included studies


ACELs: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers, ADRS: adult respiratory distress syndrome, CL: confidence interval, NR: not reported, OR: odds ratio

Table 2: Outcomes and analytic approaches of included studies

Study	Exposure	Primary outcome #1 definition	Primary outcome #2 definition	Analytical method	Factors adjusted for	Quality a ssessment
Bean et al 2020	ACEIs;ARBs	Death or admission to a critical care unit	NR	Logistic regression	Age, sex, hypertension , DM, IHD, heart failure	Moderate quality
Li et al 2020	ACEIs /ARBs	In-hospital mortality	Blood oxygen saturation levels of 93% or less	Mann-Whitney U test	Unadjusted	Moderate quality
Liu et al 2020	ACEIs;ARBs	In-hospital mortality	Chinese guidelines of 2019-nCoV infection	Multivariable logistic regression	Undear	Moderate quality
Mancia et al 2020	ACEIs;ARBs	Mechanical ventilation or death	NR	No direct analysis Estimate calculated	Unadjusted	Moderate quality
Mehra et al 2020	ACEIs ; ARBs	In hospital death	NR	Multivariable logistic-regression analysis	Age, race,coexisting conditions, medications, smoking, hospital location	Moderate quality
Reynolds et al 2020	ACEIs ; ARBs	NR	Intensive care, mechanical ventilation, or death	Propensity score model	Age; sex; race; ethnic group, coexisting conditions, and medications	Moderate quality
Yang et al 2020	ACEIs/ARBs	In hospital mortality	Respiratory failure requires mechanical ventilation, shock, combined with other organ failure requires intensive care unit care and treatment	Mann-Whitney U test	Age; sex	Moderate quality
Zeng et al 2020	ACEIs/ARBs	28-day mortality	Severity of pneumonia	No direct analysis	Unadjusted	Moderate quality
Zhang et al 2020	ACEIs/ARBs	28-day all-cause death	NR	Propensity score- matched analysis	Age, gender, comorbid conditions	High quality

ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers, NR: not reported, OR: odds ratio





	Odds Ratio			Odds Ratio		
Study or Subgroup	log[Odds Ratio] S	E Weight	IV, Random, 95% CI	IV, Random, 95% CI		
Bean et al 2020	-1.2379 0.5432	2 12.2%	0.29 [0.10, 0.84]	_		
Llu et al 2020	-1.6094 0.6143	9.6%	0.20 [0.06, 0.67]			
Mehra et al 2020	-1.1087 0.2555	55.2%	0.33 [0.20, 0.54]			
Yang et al 2020	-1.1394 0.7754	6.0%	0.32 [0.07, 1.46]			
Zhang et al 2020	-0.9943 0.4602	17.0%	0.37 [0.15, 0.91]			
Total (95% CI)		100.0%	0.32 [0.22, 0.46]	•		
	• 0.00; Chi ² = 0.73, df = 4 • Z = 6.08 (P < 0.00001)	0.01 0.1 1 10 Favours [experimental] Favours [control]	100			